Ara mostrant els elements 1-1 de 1
Soria Jiménez, Luis (Data de defensa: 2023-02-17)
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...